Journal
JOURNAL OF CELLULAR BIOCHEMISTRY
Volume 112, Issue 4, Pages 979-992Publisher
WILEY
DOI: 10.1002/jcb.22992
Keywords
NUCLEAR ENVELOPE; CELLULAR SIGNALING; LAMINOPATHIES; LAMIN; EMERIN; TRANSCRIPTION FACTOR ANCHORAGE
Categories
Funding
- Italian Istituto Superiore di Sanita 'Rare Diseases Italy-USA' [526/D30]
- Prin
- 'Fondazione Carisbo' Italy
- A.I.Pro.Sa.B., Italy
Ask authors/readers for more resources
Laminopathies are genetic diseases due to mutations or altered post-translational processing of nuclear envelope/lamina proteins. The majority of laminopathies are caused by mutations in the LMNA gene, encoding lamin A/C, but manifest as diverse pathologies including muscular dystrophy, lipodystrophy, neuropathy, and progeroid syndromes. Lamin-binding proteins implicated in laminopathies include lamin B2, nuclear envelope proteins such as emerin, MAN1, LBR, and nesprins, the nuclear matrix protein matrin 3, the lamina-associated polypeptide, LAP2alpha and the transcriptional regulator FHL1. Thus, the altered functionality of a nuclear proteins network appears to be involved in the onset of laminopathic diseases. The functional interplay among different proteins involved in this network implies signaling partners. The signaling effectors may either modify nuclear envelope proteins and their binding properties, or use nuclear envelope/lamina proteins as platforms to regulate signal transduction. In this review, both aspects of lamin-linked signaling are presented and the major pathways so far implicated in laminopathies are summarized. J. Cell. Biochem. 112: 979-992, 2011. (C) 2010 Wiley-Liss, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available